TLDR
- JNJ is investing over $1 billion to expand production capacity for its Acuvue contact lens business as part of its broader $55B U.S. manufacturing push
- A new distribution facility is being built in Jacksonville, Florida, expected to be fully operational by 2028
- Flagship drug Stelara is losing ground to biosimilar competition following its U.S. patent expiry last year
- JNJ reported Q1 EPS of $2.70 and revenue of $24.06 billion, both beating expectations, and raised its quarterly dividend to $1.34 per share
- Wall Street rates JNJ a Moderate Buy with an average price target of $266.40, implying roughly 11% upside
Johnson & Johnson opened at $240.57 on Monday, edging lower in pre-market despite announcing a $1 billion-plus investment into its eye care division. The move is part of the company’s larger $55 billion U.S. manufacturing expansion plan launched in March 2025.
The new capital is earmarked for a new distribution facility in Jacksonville, Florida, along with advanced manufacturing and packaging technologies designed to meet rising demand for Acuvue contact lenses.
JNJ says the Jacksonville facility is already under construction and is expected to be fully operational by 2028.
The company stated the investment will help it improve sight for more than 40 million patients in the U.S. and globally, while also strengthening its domestic supply chain.
This follows another $1 billion-plus commitment earlier this year to build a cell therapy manufacturing facility in Pennsylvania, showing JNJ is deploying its $55B pledge across multiple divisions.
Stelara Headwinds Drive Strategy Shift
The eye care push comes as JNJ navigates real pressure on its pharmaceutical side. Stelara, which was its flagship drug, lost U.S. patent exclusivity last year and is now up against biosimilar competition, including Amgen’s Wezlana.
In response, JNJ is leaning harder into its oncology pipeline. Earlier this month, it closed a $1 billion deal to acquire private biotech Firefly Bio to strengthen that unit.
The company is also looking to shed its slower-moving orthopedics business, signaling a sharper focus on higher-growth areas.
CEO Joaquin Duato has said JNJ has a “line of sight” to achieving double-digit sales growth by the end of the decade.
Q1 Results and Dividend Raise
JNJ’s Q1 results, reported April 14th, gave investors something to feel good about. EPS came in at $2.70, just ahead of the $2.68 consensus. Revenue hit $24.06 billion versus expectations of $23.60 billion, up 9.9% year over year.
The company set full-year 2026 EPS guidance at $11.45 to $11.65.
JNJ also raised its quarterly dividend from $1.30 to $1.34 per share, paid out on June 9th. That puts the annualized dividend at $5.36, yielding around 2.2%.
On the institutional side, Atlas Capital Advisors initiated a new position in Q4, picking up 5,769 shares worth roughly $1.19 million. Several other firms also added to existing positions.
EVP Kathryn E. Wengel sold 10,000 shares on June 11th at an average price of $241.15, totalling $2.41 million. She still holds 114,288 shares following the transaction.
Wall Street’s consensus sits at Moderate Buy, with 12 Buys and 5 Holds over the past three months. The average price target of $266.40 implies about 11% upside from current levels.
🚨 Our JUNE Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for June, highlighting companies with strong momentum that rank highly on our KO Score algorithm. We’re also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
